Raffles Medical - CGSI Research 2024-02-27: Normalisation Of Profitability In 2H23

Raffles Medical - Normalisation Of Profitability In 2H23

Published:
Raffles Medical (SGX:BSL) | SGinvestors.ioRaffles Medical (SGX:BSL)
  • - Read this at SGinvestors.io -
  • Decline in profitability of healthcare services in 2H23…

    • With most of its remaining COVID-19-related project revenue (i.e. management of COVID-19 facility) tapering off in 1H23, Raffles Medical saw its healthcare services revenue decline 45.6% y-o-y/32.6% h-o-h in 2H23. EBITDA margins also declined 34.7% points y-o-y and 26.8% points h-o-h to 15.2% in 2H23, which we think is a normalised margin level for the segment compared to pre-COVID-19 levels of 5.8%-11.8% in FY17-19, as the segment had previously included its lower margin insurance services segment.
    • - Read this at SGinvestors.io -

    …accompanied with margins recovery for its hospital services

    • Read more at SGinvestors.io.



    Above is an excerpt from a research report by CGSI Research.
    Clients of CGS International may access the full PDF report @ https://itrade.cgsi.com.sg/.



    TAY Wee Kuang CGS International Research | https://itrade.cgsi.com.sg 2024-02-27



    Price targets by other brokers at Raffles Medical Target Prices.

    Listing of research reports at Raffles Medical Analyst Reports.

    Relevant links:
    Raffles Medical Share Price History,
    Raffles Medical Announcements,
    Raffles Medical Dividend Payout Dates & Corporate Actions,
    Raffles Medical News






    Advertisement

    You May Also Like



    SGX Stock / REIT Search

    Advertisement

    Most Read

    Trust Bank Referral Code

    Advertisement